Neuroinflammation in Schizophrenia: A Critical Review and The Future (Q57820155)

1

0 references

Ceren Sahin Ozkartal

2

0 references

Gokhan Unal

3

0 references

Serdar Dursun

4

0 references

Norbert Müller

Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology

6

0 references

publication date

December 2016

0 references

published in

0 references

volume

26

0 references

issue

4

0 references

page(s)

429-437

0 references

cites work

The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Anti-inflammatory signaling in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

The dopamine hypothesis of schizophrenia: version III--the final common pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Schizophrenia: from dopaminergic to glutamatergic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

A serotonin hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Inflammation and the two-hit hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

To poly(I:C) or not to poly(I:C): advancing preclinical schizophrenia research through the use of prenatal immune activation models

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Developmental neuroinflammation and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Prenatal infection and schizophrenia: a review of epidemiologic and translational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Implications for reactive oxygen species in schizophrenia pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Microglial activation and progressive brain changes in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Clinical studies of neuroinflammatory mechanisms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Th1, Th2 and Th3 cytokine alteration in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Altered immune function in unaffected first-degree biological relatives of schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Microglial physiology: unique stimuli, specialized responses

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Inflammation in schizophrenia: A question of balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Early-life programming of later-life brain and behavior: a critical role for the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Neuroinflammation in schizophrenia especially focused on the role of microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Evidence for activation of microglia in patients with psychiatric illnesses

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Roles of glial cells in schizophrenia: possible targets for therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657

Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.5455/BCP.20161123044657